Accuracy and Cut-Off Values of Pepsinogens I, II and Gastrin 17 for Diagnosis of Gastric Fundic Atrophy: Influence of Gastritis

Author:  Dariush Nasrollahzadeh et al - PLoS ONE 6(10): e26957. doi:10.1371/journal.pone.0026957 - 2011

Dariush Nasrollahzadeh et al,
PLoS ONE 6(10): e26957. doi:10.1371/journal.pone.0026957, 2011


To establish optimal cutoff values for serologic diagnosis of fundic atrophy in a high-risk area for oesophageal squamous cell carcinoma and gastric cancer with high prevalence of Helicobacter pylori (H. pylori) in Northern Iran, we performed an endoscopy-room-based validation study.

We measured serum pepsinogens I (PGI) and II (PGII), gastrin 17 (G-17), and antibodies against whole H. pylori, or cytotoxin-associated gene A (CagA) antigen among 309 consecutive patients in two major endoscopy clinics in northeastern Iran. Updated Sydney System was used as histology gold standard. Areas under curves (AUCs), optimal cutoff and predictive values were calculated for serum biomarkers against the histology.

309 persons were recruited (mean age: 63.5 years old, 59.5% female). 84.5% were H. pylori positive and 77.5% were CagA positive. 21 fundic atrophy and 101 non-atrophic pangastritis were diagnosed. The best cutoff values in fundic atrophy assessment were calculated at PGI,56 mg/l (sensitivity: 61.9%, specificity: 94.8%) and PGI/PGII ratio,5 (sensitivity: 75.0%, specificity: 91.0%). A serum G-17,2.6 pmol/l or G-17.40 pmol/l was 81% sensitive and 73.3% specific for diagnosing fundic atrophy. At cutoff concentration of 11.8 mg/l, PGII showed 84.2% sensitivity and 45.4% specificity to distinguish non-atrophic pangastritis. Exclusion of non-atrophic pangastritis enhanced diagnostic ability of PGI/PGII ratio (from AUC = 0.66 to 0.90) but did not affect AUC of PGI. After restricting study samples to those with PGII,11.8, the sensitivity of using PGI,56 to define fundic atrophy increased to 83.3% (95%CI 51.6–97.9) and its specificity decreased to 88.8% (95%CI 80.8–94.3).


Among endoscopy clinic patients, PGII is a sensitive marker for extension of non-atrophic gastritis toward the corpus. PGI is a stable biomarker in assessment of fundic atrophy and has similar accuracy to PGI/PGII ratio among populations with prevalent non-atrophic pangastritis.


You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Please log in to react

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.